Bioventus (BVS) Capital Expenditures (2020 - 2026)

Bioventus' Capital Expenditures history runs 7 years deep, the most recent figure standing at $534000.0 for Q1 2026.

• Quarterly Capital Expenditures fell 35.35% year-over-year to $534000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 47.31% YoY) and the FY2025 annual result came in at $2.6 million, up 154.67% from the prior year.
• Capital Expenditures was $534000.0 for Q1 2026 at Bioventus, down from $580000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $4.9 million in Q3 2022 and bottomed at -$6.2 million in Q4 2022.
• A 5-year average of $343058.8 and a median of $336000.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2024 — Capital Expenditures jumped 12657.14% — and 2025, when it slumped 632.56%.
• Bioventus' Capital Expenditures stood at -$6.2 million in 2022, then surged by 100.11% to $7000.0 in 2023, then soared by 12657.14% to $893000.0 in 2024, then sank by 35.05% to $580000.0 in 2025, then retreated by 7.93% to $534000.0 in 2026.
• Business Quant data shows BVS's Capital Expenditures at $534000.0 in Q1 2026, $580000.0 in Q4 2025, and $1.8 million in Q3 2025.